3-48575497-G-A
Variant summary
Our verdict is Pathogenic. Variant got 17 ACMG points: 17P and 0B. PM1PM5PP2PP3_StrongPP5_Very_Strong
The NM_000094.4(COL7A1):c.6022C>T(p.Arg2008Cys) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00000411 in 1,460,168 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R2008G) has been classified as Likely pathogenic.
Frequency
Consequence
NM_000094.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 17 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
COL7A1 | NM_000094.4 | c.6022C>T | p.Arg2008Cys | missense_variant | 74/119 | ENST00000681320.1 | NP_000085.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
COL7A1 | ENST00000681320.1 | c.6022C>T | p.Arg2008Cys | missense_variant | 74/119 | NM_000094.4 | ENSP00000506558.1 | |||
COL7A1 | ENST00000328333.12 | c.6022C>T | p.Arg2008Cys | missense_variant | 73/118 | 1 | ENSP00000332371.8 | |||
COL7A1 | ENST00000487017.5 | n.1939C>T | non_coding_transcript_exon_variant | 39/83 | 5 |
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD3 exomes AF: 0.00000409 AC: 1AN: 244660Hom.: 0 AF XY: 0.00 AC XY: 0AN XY: 133598
GnomAD4 exome AF: 0.00000411 AC: 6AN: 1460168Hom.: 0 Cov.: 39 AF XY: 0.00000551 AC XY: 4AN XY: 726392
GnomAD4 genome Cov.: 33
ClinVar
Submissions by phenotype
Recessive dystrophic epidermolysis bullosa Pathogenic:5
Pathogenic, criteria provided, single submitter | clinical testing | Laboratory of Medical Genetics, National & Kapodistrian University of Athens | Nov 09, 2018 | PM1, PM2, PM5, PP2, PP3, PP5 - |
Pathogenic, criteria provided, single submitter | clinical testing | Center for Research in Genodermatoses and Epidermolysis Bullosa, University of Buenos Aires | Mar 14, 2022 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Neuberg Centre For Genomic Medicine, NCGM | - | The missense variant p.R2008C in COL7A1 (NM_000094.4) has been reported previously in affected indviduals (Escámez MJ et al,2018). It has been submitted to ClinVar as Pathogenic. Other variants affecting this residue have been reported previously. The p.R2008C variant is observed in 1/1,09,206 (0.0009%) alleles from individuals of European (Non-Finnish) background in gnomAD Exomes and is novel (not in any individuals) in 1000 Genomes.The p.R2008C missense variant is predicted to be damaging by both SIFT and PolyPhen2. The nucleotide c.6022 in COL7A1 is predicted conserved by GERP++ and PhyloP across 100 vertebrates. For these reasons, this variant has been classified as Pathogenic. - |
Likely pathogenic, no assertion criteria provided | clinical testing | Narges Medical Genetic and Prenatal Diagnosis Lab | - | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Laboratorio de Genetica e Diagnostico Molecular, Hospital Israelita Albert Einstein | Jun 06, 2022 | ACMG classification criteria: PS4 supporting, PM2 moderated, PM3 strong - |
Epidermolysis bullosa dystrophica Pathogenic:3
Pathogenic, criteria provided, single submitter | clinical testing | Genomic Research Center, Shahid Beheshti University of Medical Sciences | Dec 03, 2017 | - - |
Pathogenic, criteria provided, single submitter | research | Biomedical Innovation Departament, CIEMAT | Mar 08, 2011 | - - |
Pathogenic, no assertion criteria provided | clinical testing | Natera, Inc. | Apr 28, 2021 | - - |
not provided Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Sep 11, 2023 | Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 10504458, 16271705, 15816848, 10367730, 27498345, 9740253, 34426522, 20184583, 31001817, 15888141, 10084325, 34008892, 35979658, 36578049, 36287101) - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jul 09, 2023 | For these reasons, this variant has been classified as Pathogenic. This sequence change replaces arginine, which is basic and polar, with cysteine, which is neutral and slightly polar, at codon 2008 of the COL7A1 protein (p.Arg2008Cys). The frequency data for this variant in the population databases is considered unreliable, as metrics indicate poor data quality at this position in the gnomAD database. This missense change has been observed in individual(s) with dystrophic epidermolysis bullosa (PMID: 9740253, 10084325, 15888141, 16271705, 20184583). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 522791). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed at Invitae for this missense variant, however the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on COL7A1 protein function. This variant disrupts the p.Arg2008 amino acid residue in COL7A1. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 9326325, 10084325, 10504458). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. - |
Recessive dystrophic epidermolysis bullosa;C0268371:Dominant dystrophic epidermolysis bullosa with absence of skin;C0432321:Pretibial dystrophic epidermolysis bullosa;C0432322:Generalized dominant dystrophic epidermolysis bullosa;C1275114:Epidermolysis bullosa pruriginosa;C1843761:Nonsyndromic congenital nail disorder 8;C1851573:Transient bullous dermolysis of the newborn Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Mar 17, 2024 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at